Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Non-Current Assets (2022 - 2025)

Historic Other Non-Current Assets for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $881000.0.

  • Atara Biotherapeutics' Other Non-Current Assets fell 7375.63% to $881000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $881000.0, marking a year-over-year decrease of 7375.63%. This contributed to the annual value of $3.1 million for FY2024, which is 3594.14% down from last year.
  • As of Q3 2025, Atara Biotherapeutics' Other Non-Current Assets stood at $881000.0, which was down 7375.63% from $927000.0 recorded in Q2 2025.
  • Atara Biotherapeutics' Other Non-Current Assets' 5-year high stood at $51.4 million during Q1 2022, with a 5-year trough of $881000.0 in Q3 2025.
  • Moreover, its 4-year median value for Other Non-Current Assets was $4.8 million (2023), whereas its average is $7.7 million.
  • Data for Atara Biotherapeutics' Other Non-Current Assets shows a peak YoY increase of 902.17% (in 2023) and a maximum YoY decrease of 8657.18% (in 2023) over the last 5 years.
  • Atara Biotherapeutics' Other Non-Current Assets (Quarter) stood at $7.0 million in 2022, then tumbled by 30.98% to $4.8 million in 2023, then plummeted by 35.94% to $3.1 million in 2024, then plummeted by 71.61% to $881000.0 in 2025.
  • Its last three reported values are $881000.0 in Q3 2025, $927000.0 for Q2 2025, and $2.8 million during Q1 2025.